WO1987007644A1 - TRANSLATION OF mRNA - Google Patents

TRANSLATION OF mRNA Download PDF

Info

Publication number
WO1987007644A1
WO1987007644A1 PCT/GB1987/000390 GB8700390W WO8707644A1 WO 1987007644 A1 WO1987007644 A1 WO 1987007644A1 GB 8700390 W GB8700390 W GB 8700390W WO 8707644 A1 WO8707644 A1 WO 8707644A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
rna
cat
leader
mrna
Prior art date
Application number
PCT/GB1987/000390
Other languages
French (fr)
Inventor
Thomas Michael Aubrey Wilson
Original Assignee
Diatech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10598884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1987007644(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Diatech Limited filed Critical Diatech Limited
Priority to DE3750422T priority Critical patent/DE3750422T2/en
Priority to EP87903719A priority patent/EP0270611B1/en
Publication of WO1987007644A1 publication Critical patent/WO1987007644A1/en
Priority to US08/046,358 priority patent/US5489527A/en
Priority to US08/474,010 priority patent/US5891665A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12N9/1033Chloramphenicol O-acetyltransferase (2.3.1.28)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478Aspartic endopeptidases (3.4.23)
    • C12N9/6481Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031Beta-glucuronidase (3.2.1.31)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/55Vector systems having a special element relevant for transcription from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/10Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/60Vectors comprising a special translation-regulating system from viruses

Definitions

  • RNA viruses contain either positive or negative single- stranded RNA or double-stranded RNA.
  • the class of RNA viruses include the majority of plant viruses (over 90%) , some animal viruses and several bacteriophage .
  • Turnip yellow mosaic virus genome RNA (Filipowicz and Haenni, Proc . Natl. Acad. Sci. USA 7JL 3111 (1979)) , brome mosaic virus RNA 3, alfalfa mosaic virus RNA 4 (Goelet e t. al .. Proc. Natl. Acad. Sci. USA 5818 (1982)) ; Rous Sarcoma virus (J.L. Darlix e_t al.. Nuc . Acids Res. 1_, 5183 (1982)) .
  • TMV RNA vul are strain (Goelet e_t. al.. Proc. Natl. Acad. Sci. USA 7.9. 5818 (1982))
  • an 81 base oligonucleotide was synthesised containinuß the DNA sequence complementary to the 67 base sequence upstream of the AUG initiation codon of the 126 kDa open reading frame, but not including the 5' cap (m'Gppp and adjacent G residue) .
  • This sequence is called omega prime.
  • a HindiII site was incorporated at the 5' end and a Sal I site at the 3' end of this oligonucleotide .
  • C-labelled marker proteins (Amersham International, pic) were loaded on track M. Their respective sizes in kilodaltons (kDa) are shown on the left.
  • the dried gel was autoradiographed for 3 days at room temperature.
  • template additions were: track 1, H2O (endogenous translation) ; track 2, Bglll- linearized pJII102 DNA; track 3, CAT RNA; track 4, omega prime-CAT RNA; track 5, 5 '-capped CAT RNA; track 6, 5 '- capped-omega prime-CAT RNA; track 7, EcoRI- linearized pJII103 DNA; track 8, NPTII RNA: track 9, omega prime-NPTII RNA; track 10,.
  • This dsDNA fragment was then inserted into the various leader-reporter (GUS) gene plasmids between the SP6 promoter (silent in E ⁇ coli in vivo) and the 5' -leader const .uct of interest.
  • GUS leader-reporter

Abstract

Use of the 5'-leader sequence of an RNA virus up to the first initiation codon of the viral RNA (or a derivative or portion thereof), either as RNA or a complementary DNA, as an enhancer of translation of mRNA when the 5'-leader RNA is contiguous with the mRNA.

Description

Translation of mRNA
This invention relates to enhancers of the translation of mRNA.
The mechanisms by which eukaryotes and. prokaryotes initiate translation are known to have certain features in common and to differ in others. Eukaryotic messages are functionally onocistronic , translation initiates at the 5' end and is stimulated by the presence of a cap structure (m7G5'ppp5'G... ) at this end (Shatkin, Cell 9. 645 (1976)) . Prokaryotic messages can be polycis tronic , can initate at sites other than the 5' terminus, and the presence of a cap does not lead to translational stimulation. Both eukaryotes and. prokaryotes begin translation at the codon AUG, although prokaryotes can also use GUG . Translation in both is stimulated by certain sequences near the. start codon. For prokaryotes, it is the so-called Shine-Dalgarno sequence (a purine rich region 3-10 nucleotides upstream from the initiation codon) . For eukaryotes, it is a purine at the -3 position and a G residue in the +4 position (where the A of the AUG start codon is designated +1) , plus other sequence requirements involved in finer tuning. This is part of the "relaxed" version of the scanning model (Kozak, Nuc . Acids. Res. !_2_, 857 (1984)) whereby a 40S ribosomal sub-unit binds at the 5' end of the eukaryotic mRNA and proceeds to scan the sequence until the first AUG, which meets the requirements of the model, is encountered, at which point a 60S sub-unit joins the 40S sub-unit, eventually resulting in protein synthesis. Reference can be made in this connection to the following publications by Kozak : Cell 15. 1109 (1978) , Nuc . Acid. Res. 9_, 5233 (1981) and Cell 44_, 283 (1986) .
Beyond these sequence requirements in and about the initiation codon, there are no additional regions of mRNA which are known to enhance translation reproducibly .
During, eukaryotic transcrip ion, sequences known as "enhancer" regions can provide transcriptional stimulation.
RNA viruses contain either positive or negative single- stranded RNA or double-stranded RNA. The class of RNA viruses include the majority of plant viruses (over 90%) , some animal viruses and several bacteriophage .
One of the most widely studied of RNA viruses is tobacco mosaic virus (referred to hereinafter as TMV) . The complete nucleotide sequence of TMV is known (Goelet et al . , Proc. Natl. Acad. Sci. USA 7_9. 5818 (1982)) . The 5'- region of TMV RNA was first isolated in 1965 as an RNase ]_-resistant fragment 70 nucleotides long (Mundry, Z. Vererbungsl. 9_7., 281 (1965)) and free of internal G residues (Mandeles, J. Biol. Chem. 243. 3671) . This region (later referred to as omega, Mandeles J. Mol. Biol. Chem. 243 3671) was sequenced (Richards e_t aL. Eur . J. Biochem. 4. 513 (1978)) and shown to form disome initiation complexes with wheat germ ribosomes. One ribosome occupies the AUG initiation site of the 126 KDa protein coding region and the second binds to the upstream leader sequence (Filipowicz and Haenni, Proc . Natl. Acad. Sci. USA 26., 3111 (1979) ; Konarska et al. , Eur . J. Biochem. 114. 221 (1981)) . Recent additional evidence to support the role of omega in ribosome association comes from the uncoating/gene expression data of Wilson and co-workers, (reviewed in J. Gen. Virol. 6_6_, 1201 (1985) and UCLA Symp , 5_4 159 (1987)) . It was observed in various i_n vitro translation systems that TMV particles are uncoated by the binding of ribosornes to the 5' end and their translational movement toward the 3' terminus.
It has now been found that the 5' - regions of RNA viruses act as enhancers of translation of mRNA.
According to a first aspect the present invention provides mRNA including the 5' - leader sequence of an RNA virus up to the first initiation codon of the viral RNA (or a derivative or portion thereof) , the mRNA also including downstream sequence not derived from the virus providing the leader sequence.
According to a second aspect the invention provides a DNA sequence complementary to the 5'- leader sequence of an RNA virus, up to the first initiation codon of the viral RNA (or a derivative or portion thereof) .
According to a third aspect the invention provides a DNA sequence comprising a promoter, a sequence complementary to the 5' - leader sequence of an RNA virus up to the first initiation codon of the viral RNA (or a derivative or portion thereof) and an open reading frame including an appropriate initiation codon. The invention also provides an expression vector including such a DNA sequence.
According to a fourth aspect the invention provides the use of the 5' - leader sequence of an RNA virus up to the first initiation codon of the viral RNA (or a derivative or portion thereof) , either as RNA or as complementary DNA, as an enhancer of translation of mRNA when the 5' - leader RNA is contiguous with the mRNA.
Most RNA viruses which have been sequenced contain 5'- leader sequences, i.e. sequences at the 5'- end up to but not including the first initiation codon. Appropriate 5'- leader sequences from any RNA virus may be used as a translational
« enhancer according to the invention.
As noted above, the 5'- leader sequence of TMV plus the AUG initiation codon is known as omega and Its nucleotide sequence is known (Richards et al . Eur . J. Biochem. 84. 513 (1978)) so that cDNA can be prepared synthetically. The omega prime (JL' , see Figure 1) sequence of TMV represents the preferred translational enhancer according to the invention.
Information is also available about the translational enhancement by 5'- leader sequences of other RNA viruses • including the following:
Turnip yellow mosaic virus genome RNA (Filipowicz and Haenni, Proc . Natl. Acad. Sci. USA 7JL 3111 (1979)) , brome mosaic virus RNA 3, alfalfa mosaic virus RNA 4 (Goelet e t. al .. Proc. Natl. Acad. Sci. USA 5818 (1982)) ; Rous Sarcoma virus (J.L. Darlix e_t al.. Nuc . Acids Res. 1_, 5183 (1982)) .
In any particular case it will almost certainly be possible to vary the natural 5' - leader sequence in such a way that its function as a translational enhancer Is modulated but not destroyed. Such variants are referred to herein as "derivatives" and derivatives of the natural sequence and their use as translational enhancers form part of the present invention. It may also be the case that parts only of the natural 5' - leader sequence (or a derivative sequence) are required to provide transla ional enhancement. Such parts of the sequence are referred to herein as "portions" and portions of the natural sequence or of derivatives thereof and their use as transla ional enhancers form part of the present invention.
In any particular case, determination of the nucleotide sequence of the 5' - leader of an RNA virus should be within the expertise of a man of ordinary skill in the art using known and readily available techniques . Similarly, identification of those parts of the natural 5'- leader sequence which are essential for transla ional enhancement and those which can be modified or omitted (i.e. the identification of derivatives and portions of the natural sequence) is a matter which can be determined by routine experimentation. The 5'- leader sequences of RNA viruses (or derivatives or portions thereof) can be used as such as translational enhancers according to the invention by ligating them upstream of an appropriate mRNA using for example T4 RNA ligase. The 5' - leader sequence may be immediately adjacent to the initiation codon of the downstream mRNA, or it may be spaced therefrom by an intervening sequence. However, it is preferred to use the 5' - leader sequence in the form of complementary DNA. The cDNA can be obtained in any manner which is desired. However in view of the relatively short length of the 5' - leader sequences In question it will usually be most convenient to synthesise the cDNA chemically. The cDNA will generally be incorporated into an expression vector. An expression vector is any vector capable of expressing those DNA sequences contained therein which are operably linked to other sequences capable of effecting their expression. An expression vector will usually contain a DNA sequence comprising a promoter, the sequence complementary to the 5'- leader sequence of an RNA virus up to but not including the first initiation codon of the viral RNA (or a derivative or portion thereof) and an open reading frame Including an appropriate initiation codon. The open reading frame will generally code for one or more proteins of interest. The expression vector may be introduced directly into the host cell stably or transiently where the DNA sequence is expressed by transcri tion and translation. In the case of stable expression the vector must be replicable in the host either as an episome or as an integral part of the chromosomal DNA. Alternatively the expression vector can be transcribed n vitro and the RNA introduced directly into the cell for transient expression.
The translational enhancers according to the invention can be used in any situation where it is desired to enhance the translational efficiency of mRNA. However it should be noted that the effect of the enhancers is most marked in the case of an mRNA which is otherwise poorly translated. Thus the addition of either a cap or an enhancer according to the invention or both will stimulate translation. In the case of an mRNA already bearing a cap the effect of the enhancer according to the invention, is still present.
The translational enhancers according to the invention are effective in many different types of expression system, for example plant cells, bacteria and animal cells although a particular enhancer may be more suitable for one system rather than another. For example during testing in vitro the omega sequence of TMV appears to show a greater degree of enhancement in the wheat germ system and E . coli than in the rabbit reticulocyte lysate system although enhancement of translation is observed in all three systems. The matching of particular enhancers to particular expression systems will generally be a matter well within the expertise of the man of ordinary skill . In general the translational enhancers according to the invention can be used with advantage in any case where the value of an organism or cell line to commerce, Including agriculture, is determined by the level of expression of one of its natural genes or of an artifically introduced gene.
(i) In the manufacture of commercially useful proteins in genetically engineered organisms or cell lines.
(il) In fermentation where ' the rate of production of a product of intermediary metabolism catalysed by enzymes can be enhanced by increasing the rate of synthesis of a particular enzyme.
(iii) In viral cross -protection where the effects of a viral infection can be reduced by prior exposure to an attenuated form of the virus and it is advantageous to increase the level of protection by increasing 'the level of production of the component which provides the protection. For example plants can be protected against infection by TMV by exposing them to a genetically engineered strain of Agrobacterium which contains a cDNA copy of that portion of the TMV RNA which codes for the viral coat protein. Bacterial cDNA inserted in the plant genome continually expresses the coat protein which protects the plant against infection by the virus itself.
(iv) In the genetic engineering of plants where a property such as herbicide resistance is installed by artificial modification of the Intermediary metabolism of the p l ant .
(v) In the expression of a partial clone of a gene, for example where it is desired to raise antibodies to the product of expression of the partial clone.
The invention is illustrated further by the following experimental work. EXPERIMENTAL mRNA
Chimaeric mRNA according to an embodiment of the invention was produced in the following manner, as illustrated in Figure 1.
Using the sequence of TMV RNA vul are strain (Goelet e_t. al.. Proc. Natl. Acad. Sci. USA 7.9. 5818 (1982)) , an 81 base oligonucleotide was synthesised containin „ the DNA sequence complementary to the 67 base sequence upstream of the AUG initiation codon of the 126 kDa open reading frame, but not including the 5' cap (m'Gppp and adjacent G residue) . This sequence is called omega prime. A HindiII site was incorporated at the 5' end and a Sal I site at the 3' end of this oligonucleotide . A second oligonucleotide of 20 bases, including 13 bases at the 3' end of the omega prime sequence and a Sal I site, was synthesized as a primer for the synthesis of the second strand. After annealing, second strand synthesis was completed using the Klenow fragment of DNA poly erase I.
The resulting double- stranded 81 bp fragment was digested with Hindlll/Sal I to create a 79 bp fragment with s ingle - s tranded cohesive ends and inserted into the corresponding sites of pUC19. The fact that the synthesis had resulted in the correct orientation of the omega prime sequence of TMV was verified by sequence analysis using the dideoxy chain termination method (Sanger e_t. al_ . , Proc . Natl. Acad. Sci. USA 1_ _, 5463 (1977)) . The fragment containing omega prime of TMV was then introduced into the Hindlll/Sal I sites of plasmid pJIIl to result in pJIHOl. pJIIl is derived by inserting the TMV origin of assembly sequence as a BamHI fragment into the corresponding site of pSP64 (Melton, Nuc . Acids Res. 1_2. 7035 (1984)) and modifying the Sπtal site to a Bgl II site (Sleat e_t a\_. Virology 155. 299 (1986)) .
A 779 bp Sal I ended fragment from pCMl (Close and Rodriguez , Gene 2J)_, 305 (1982) ) containing the chloramphenicol acetyltransferase gene (CAT) of Tn9 was introduced into the Sal I site of pJIIl and pJIHOl, resulting in pJII2 and pJII102, respectively. A 1.2 kb Bgl Il/Sal I fragment from pKNR-H (Gallie e_t. a _. , J. Bacteriol. 161. 1034 (1985)) containing the neomycin phosphotransferase II gene (NPTII) of Tn5 was made blunt ended with Klenow fragment and introduced into the Ace I site of pJIIl and pJIHOl to result in pJII3 and pJII103, respectively. Correct orientation of both the CAT and NPTII genes was verified by restriction fragment analysis.
After linearisation of pJII2 and pJII102 with Bgl II and pJII3 and pJII103 with EcoRI . RNA transcripts of each were made using SP6 RNA polymerase. Capped versions of each were also made using GpppG and SP6 polymerase reaction conditions which ensure comparable yields of capped transcripts. Equivalent yields of RNA from the capped and uncapped reactions and for the constructs with or without the omega sequence were verified by denaturing formaldehyde - agarose gels .
Equivalent amounts of the various CAT containing transcripts and the NPTII containing transcripts were added to the rabbit reticulocyte lysate (MDL) , wheat germ S-30 (WG) and E . coli S-30 n vitro translation systems under standard reactio'n conditions. The resulting polypeptide products were labelled with 35S -methionine .
Figures 2 and 3 show the SDS-PAGE analysis of the translation products from MDL (Fig. 2, tracks 1 to 11), WG (Fig. 2, tracks 12 to 22) and E . coli (Fig. 3) . In Figure 2 template additions were: tracks 1 and 12, H2O (endogenous translation) ; tracks 2 and 13, BgllI-linearized pJII102 DNA; tracks 3 and 14, CAT RNA; tracks 4 and 15, omega prime-CAT RNA; tracks 5 and 16, 5' -capped CAT RNA; tracks 6 and 17, 5'- capped-omega prime-CAT RNA; tracks 7 and 18, EcoRI - linearized pJII103 DNA; tracks 8 and 19, NPTII RNA: tracks 9 and 20, omega prime-NPTII RNA; tracks 10 and 21, 5' -capped NPTII RNA; tracks 11 and 22, 5 ' -capped- omega prime-NPTII RNA. C-labelled marker proteins (Amersham International, pic) were loaded on track M. Their respective sizes in kilodaltons (kDa) are shown on the left. The dried gel was autoradiographed for 3 days at room temperature. In Figure 3 template additions were: track 1, H2O (endogenous translation) ; track 2, Bglll- linearized pJII102 DNA; track 3, CAT RNA; track 4, omega prime-CAT RNA; track 5, 5 '-capped CAT RNA; track 6, 5 '- capped-omega prime-CAT RNA; track 7, EcoRI- linearized pJII103 DNA; track 8, NPTII RNA: track 9, omega prime-NPTII RNA; track 10,. 5' -capped NPTII RNA; track 11, 5' - capped-omega prime-NPTII RNA. ^C-labelled marker proteins were loaded on track M and their sizes (in kDa) are shown on the left. The dried gel was autoradiographed for 3 days at room temperature. It should be noted that although the E . coli S-30 system is a transcriptionally active system, the native E . coli RNA polymerase does not recognise the SP6 promoter .
The following Table 1 shows the stimulating effect of the omega prime sequence. Zones from gels shown in Figures 2 and 3 were excised and the radioactivity in each band of product of translation was measured and the data normalised In each case to that from RNA not containing the omega prime sequence. Expressing the data in this way eliminates any stimulating effect of the cap alone and shows only the stimulating effect of the omega prime sequence. Table i mRNA WG MDL E. coli
CAT 1 1 1 omega prime-CAT 10 1.2 11 r
GpppG-CAT 1 1 1
GpppG-omega prime-CAT 3.8 2.2 2.7
NPTII omega prime-NPTII 71 17.8 74
GpppG-NPTII 1 1
GpppG-omega prime-NPTII 9.5 1.9 9.6
DISCUSSION
The presence of the omega prime region of TMV stimulates the expression of transcripts containing either the CAT or NPT II sequences in either the capped or uncapped state. Stimulation was most marked with the translationally inefficient NPTII transcripts. Thus, the Tn5 fragment containing the NPTII gene contains an additional AUG immediately upstream from the AUG start codon of the NPTII gene. In addition, the "Kozak rules" (see the papers by Kozak referred to above) would suggest that the region about the NPTII start codon constitutes a poor signal for translational initiation. As seen in WG and MDL (Figure 2, lanes 8 and 19) , the NPTII transcript without either a cap or omega prime functions poorly. The addition of a cap or omega prime improves translation although the presence of omega prime has a greater stimulatory effect than the presence of a cap alone. E . coli translational machinery, although not cap-dependent , is greatly stimulated by the presence of the omega prime sequence (Figure 3, lanes 4, 6, 9 and 11). In E . coll . addition of a cap to the omega prime sequence on CAT or NPTII mRNA did little to enhance its translation whereas addition of omega prime to capped,CAT or NPTII mRNA resulted In greater enhancement.
CAT gene mRNA, even without a cap or the omega prime sequence, functions more efficiently in the eukaryotic systems. The first AUG from the 5' terminus is the start codon for CAT and the sequence in and about the start codon conforms well to the "Kozak rules" . This is most evident in the MDL system where a much lower mRNA concentration was required to prevent exhaustion of the available 3^S- methi'onine pool. Not surprisingly then, the presence of the omega prime sequence in CAT mRNA was less stimulatory. MDL is thought less cap-dependent than WG , however the presence of a cap on the NPTII transcript had a slight stimulatory effect (Figure 2, lanes 8 and 10) , whereas its presence on the CAT transcript had little effect (Figure 2, lanes 3 and 5) . CAT mRNA alone was much less active in the WG system. As a result, the presence of either a cap or the omega prime sequence or both was highly stimulatory (Figure 2, lanes 14 to 17) . In WG , addition of a cap to the omega prime sequence on NPTII mRNA (Figure 2, lanes 20 and 22) did little to enhance its translation whereas addition of omega prime to capped or uncapped NPTII mRNA (Figure 2, lanes 19 and 21) resulted in a greater enhancement.
Therefore the presence of the omega prime sequence enhances translation in both eukaryotic (MDL and WG) and prokaryotic systems. This is consistent with the ability of TMV particles to be uncoated and the RNA translated by eukaryotic or prokaryotic translational machinery. The omega prime sequence often has a greater stimulatory effect on the expression of transcripts than does the presence of a cap alone. In addition, the omega prime sequence enhances translation under conditions where capping does not, e.g. in the prokaryotic and, to some extent, the MDL systems. FURTHER EXPERIMENTAL WORK
Chimaeric RNA constructs including CAT mRNA and derivatives or portions of the omega prime leader sequence were made in an analogous manner to that described above, the initial synthetic DNA sequence being chosen to produce the required RNA. As shown in Figure 4, there were five deletions (referred to as Δl to Δ5) , one A -> C transversion and one [C,A]n -> [U] n substitution.
Further chimaeric RNA constructs containing CAT mRNA were made in an analogous manner with 5' -leader sequences of viruses other than TMV (Ul , vul re . or common strain) , namely the tomato strain of TMV (SPS isolate) , Turnip Yellow Mosaic Virus (TYMV) , Brome Mosaic Virus RNA 3 (BMV 3) , Rous Sarcoma Virus partial leader (RSV) and Alfalfa Mosaic Virus RNA 4 (A1MV4) . The initial DNA sequences synthesised and restriction site diagrams are shown respectively in Figures 5 to 9.
A further set of RNA constructs was prepared in an analogous manner, but with the E . coli reporter gene β - glucuronidase (GUS) in place of CAT. The leader sequences used were either polylinker (for comparison purposes) or UI omega (i.e. omega prime from TMV) or the derivatives and portions of omega prime and other viral leaders as described above. The GUS gene was used either in an artificial "good" Kozak context (see p. 33. r_§_. Table 9) or in the native "bad" Kozak context as a Sail fragment from pRAJ235/240 (Jefferson et al. Proc. Natl . Acad. Sci. 8_3_ 8447 (1986)) . The leader sequences and restriction site diagrams are shown in Figures 10 to 13. The expression of the reporter gene was determined fluorimetrically as described by Jefferson e_t. a_i. Proc. Natl. Acad. Sci. 8_3. 8447 (1986) .
In addition to the three i_n vitro translation systems described above , two in vi o systems were used: microinj ection of Xenopus laevis oocytes and electroporation of tobacco (Hicotiana Tabacum cv ' Xanthi) mesophyll protoplasts. The respective techniques were as follows:
Two ng of each synthetic SP6 mRNA (or their corresponding DNA templates) were microinj ected into the cytoplasm of stage 6 X. laevis oocytes in batches of 30 using standard procedures (Colmaή A. In Hames , B.D. and Higgins, S.J. (eds.) , Transcription and Translation: A Practical Approach, IRL Press, Oxford. 271 (1984)) . Oocytes were incubated for 18 hours in Modified Barths ' Saline (MBS) , then washed briefly in distilled water. Extracts from Xenopus oocytes were prepared by resuspending each sample in 0.25 M Tris-HCl, pH 7.4, containing 10 mM DTT (17 μl/oocyte) , followed by sonication for 15 sec. Insoluble material was removed by microcentrifugation for 15 min. and fractions of the resultant extract representing equivalent numbers of oocytes were assayed for CAT or GUS activity by published procedures (CAT: Gallie e_t. a . Nuc . Acids. Res. 1_5_ 3257 (1987); GUS: Jefferson e_t a . Proc. Natl. Acad. Sci. 8_3_ 8447 (1986)). s> Mesophyll protoplasts were isolated from leaves of . tabacum (cv. Xanthl) and stored in 0.7 M mannitol. The protoplasts (10°) were centrifuged at 60xg. for 3 min, resuspended in 1 ml ice-cold 0.7 M mannitol containing the RNA (8μg) , transferred to the electroporation cell and given a single voltage pulse (2.5 kV/cm) by discharging a 50 nF capacitor through the cell. The pulse had a rapid rise-time (less than 1 μs) and an 'exponential decay with a half-life of about 5 μs . Electroporated protoplasts were stored at 0-4°C for 10 min. Ten mis of 0.7 M mannitol were added and the protoplasts recovered by centrifugation at 60x . for 3 min. The protoplasts were then resuspended in culture medium and incubated at 25°C for 21 hours in 9 cm-diameter Petri dishes.
Each sample of electroporated protoplasts was sedimented, resuspended and sonicated in 150 μl of 0.25 M Tris-HCl, pH 7.4 containing 2 M leupeptin and 10 mM dithlothreitol (DTT) for CAT assays or 50mM sodium phosphate pH 7.0, lOmM 2-mercapto ethanol for GUS assays. Extracts were microcentrifuged at 10 , OOOxg. for 10 min at room temperature or 4°C.
Figure 14 shows the effect of omega prime on the expression of capped or uncapped CAT RNAs in electroporated tobacco protoplasts. Each origin spot received extract equivalent to 5 x 10^ viable protoplasts. For each sample, the conversion (%) of substrate ^ C-chloramphenicol) into its mono -acetylated forms '(indicated on the left) is shown at the top of the track. Electroporated RNAs or standards were: track 1, no RNA (mock) ; track 2, CAT RNA; track 3, omega prime-CAT RNA; track 4, 5' -capped CAT RNA; track 5, 5' - capped-omega prime-CAT RNA; track 6, 0.1 unit purified CAT enzyme added to an equivalent volume of extract as for track 1; track 7, 0.1 unit purified CAT enzyme alone. The dried tic plate was autoradiographed for 2 days before removing and determining the radioactivity in the relevant * C-labelled spots of mono - acetylated products (3-Ac/l-Ac) , % conversion data reflects the relevant CAT activity in the extract. Omega prime (+/- a 5' -cap) was the most stimulatory of CAT RNA expression.
Figure 15 shows the effect of omega prime on the expression of capped or uncapped CAT RNAs microinj ected into X. laevis oocytes. An equal amount of each CAT RNA-construet or linearized DNA template (2 ng) was injected per oocyte, throughout. Equal oocyte extract volume (equivalent to 0.3 x cell) were assayed in each case, unless stated otherwise. Conversion (%) of ^C - chloramphenicol into its mono- acetylated forms, is shown at . the top of each track. In tracks 5 and 6, conversion (%) into the di -acetylated form is indicated by *. Microinj ected RNAs or standards were: track 1, no RNA (mock) ; track 2, Bgill- 1inearized pJII102; track 3, CAT RNA; track 4, omega prime-CAT RNA; track 5, 5' -capped CAT RNA; track 6, 5 '-capped-omega prime-CAT RNA; track 7, as for track 5 but 20-fold diluted extract; track 8, as for track 6 but 20-fold diluted; track 9, 0.1 unit purified CAT enzyme added to an equivalent volume of extract as in track 1; track 10, 0.1 unit purified CAT enzyme alone. The dried tic plate was autoradiographed at room temperature for 18 hours, before excising and counting the relevant -"-^C - labelled spots.
The following Tables show the further results obtained.
Tab l e 2
Effect of deletions and other sequence alterations on translational enhancement by omega prime. Chloramphenicol acetyltransferase expression in RNA-microinj ected Xenopus oocytes .
RNA inj ected % c onve r s i o n o f ^C - chloroamphenico1 to the 1- and 3- monoacetylated forms
Nil (mock) 0.1
CAT 4.5
Omega prime CAT 34.2
Δl - CAT 17.2
Δ2 - CAT 9.7
Δ3 - CAT 17.6
Δ4 - CAT 14.6
Δ5 - CAT 17.9
A -> C transversion - CAT 15.7
[C,A]n -> [U]n substitution - CAT 34.3 0.1 units CAT (pure enzyme) 1.2
All RNA's were uncapped
The above results show that omega prime enhances translation of CAT. Deletions 1 to 5 reduce this effect without destroying it entirely. The same is true of the A -> C transversion. The [U]n substitution has little effect, if any . Table 3 Effect of untranslated 5' -leader sequences from different viruses on the level of expression of chloramphenicol acetyltransferase after microinj ec ion of mRNA into Xenopus oocytes.
RNA injected % conversion of ^^G-chloroamphenicol to the 1- and 3- monoacetylated forms
Nil (mock) O.l'
CAT 6.3
Omega Ul CAT 46.5
Omega (SPS) CAT 35.8
TYMV CAT 1.3
BMV3 CAT ' 5.0
RSV CAT 5.4
A1MV4 6.7
0.1 Units CAT (pure enzyme) 1.3
All RNAs were uncapped
Omega Ul derives from the standard strain of TMV (Vulgare) . Omega SPS is from the tomato strain of TMV. TYMV: turnip yellow mosaic virus leader. BMV3 : brome mosaic virus RNA3.
RSV: a partial leader sequence from Rous Sarcoma virus. A1MV4 : alfalfa mosaic virus RNA4.
The above results show that omega prime from TMV Ul enhances translation of CAT RNA in this system. TMV tomato strain o.mega prime also does so, but a little less well. Other viral leaders have little or no effect, TYMV leader may be inhibitory.
Tab l e 4
Effects of different 5'- non- translated leader sequences with or without a 5 ' -cap on in vitro translation of chloramphenicol acetyltransferase mRNA in a wheat germ cell- free system. (The results as shown below have been normalized to the unmodified CAT mRNA leader sequence which was taken as 1.0 to show fold-stimulation over CAT mRNA alone) .
RNA added Uncapped capped
CAT 1.0 1.0
Omega prime CAT 2.8 3.7
Δl-CAT 1.2 0.6
Δ2-CAT 2.0 1.8
Δ3-CAT 1.5 1.3
Δ4-CAT 3.0 1.5
Δ5-CAT 1.5 0.7
A -> C transversion-CAT 3.3 2.9
[C,A]n->[U]n substitution-CAT 2.1 3.4
TMV Tomato strain Omega prime-CAT 1.7 3.0
TYMV-CAT 0.3 3.0
BMV3-CAT 1.4 2.8
RSV-CAT 0.6 2.5
A1MV4-CAT 2.1 2.3 Note : these figures represent comparisons of proportional stimulations of translation produced by the inclusion of different sequences at the 5' end of the CAT message. Translations were done with capped or with uncapped messages. Each column represents the yield of radioactive CAT protein recovered by excision from an independent gel (as in Figures 2 and 3) . The bands were cut out, counted, and have been normalised to a band for which the mRNA was unmodified CAT message.
The above results show that omega prime enhances in this system, with or without 5' -capping. The other viral leader se uences and derivatives or portions of omega prime enhance translation to varying extents, but rarely significantly more than omega prime itself.
Tab l e 5
Effects of different non- translated leader sequences, all without a 5' -cap structure, on in vitro translation of chloramphenicol acetyltransferase mRNA in an E . coli cell- free system.
RNA added Uncapped
CAT 1.0
Omega prime CAT 9.0
Δl - CAT 3.3
Δ2 - CAT 2.5
Δ3 - CAT 6.3
Δ4 - CAT 4.2
Δ5 - CAT 3.8
*
A -> C transversion CAT 4.1
[C,A]n ->[U In sub£ ;titution CAT 1.9
TMV Tomato strain Omega CAT 6.6
TYMV CAT 0.2
BMV3 CAT 3.7
RSV CAT 1.5
A1MV4 CAT 1.4
The above results show that omega prime, some of its derivatives, and tomato strain omega prime enhance translation to the greatest extent. Most of the other sequences also enhance, but to varying extents. E . coli does not require a 5' cap for translation. Tab l e 6
Effect of different leaders on the translation of β - glucuronidase mRNA (from pRAJ235/240) electroporated into tobacco protoplasts.
GUS mRNA nmoles 4-methyl umbelliferyl Fold construct glucuronide cleaved min'^/μg Stimulation used * protein in protoplast extract
[Blank] (no mRNA)
Uncapped Leader
235 [SP6 transcript, polylinker leader. ] <0.01 1
Omega prime (Ul)-235 0.25 >25
Omega prime (SPS)-235 0.15 >15
TYMV -235 <0.01
A1MV4 -235 <0.01
BMV3 -235 <0.01
RSV -235 <0.01
Capped Leader capped 235 [SP6 transcript polylinker leader] 0.03 1 capped Omega prime -235 0.54 18 capped Omega prime
(SPS) -235 0.43 14 capped TYMV -235 <0.01 capped A1MV4 -235 0.23 8 capped BMV3 -235 0.23 8 capped RSV -235 0.21 7 capped Δl -235 0.55 18 capped Δ2 -235 0.50 17 capped Δ3 -235 0.32 11 capped Δ4 -235 0.54 18 capped Δ5 -235 0.54 18 capped A->C transversion
-235 0.69 23 capped [C,A]n->[U]n substitution <0.01
(blank value subtracted from all others ) (* Constructs were "bad" GUS ex. pRAJ (235/240) , with or without a 5' cap)
All mRNA constructs were electroporated at 8μg/ml and washed protoplasts incubated for 20 hours as described (Gallie e Z. a_i Nuc. Acids. Res. 15., 3257 (1987)) .
The sequence of the "Bad" Kozak construct (235) leader is as follows : ex SP6 plasmid Sal I
5 ' GAA UAC AAG CUU GGG CUG CAG GGUU<C GAC CGG UCA GUC CCU U AUG U
Hind III The insertion of Omega prime into the polylinker is as below: ex SP6 plasmid Sal I i f
GAA UAC AAG CUU(omega prime ) LGU~C G~AC) CGG UCA GUC CCU A AUG U
Hind III wherein omega prime sequence is as below: - UAU UUU UAC AAC AAU UAC CAA CAA CAA CAA ACA ACA AAC AAC AUU ACA AUU ACU AUU UAC AUU UAC A and the deleted omega prime derivatives, etc follow accordingly .
Messenger RNAs encoding calf preprochymosIn or chicken prelysozyme were synthesized in vitro . with or without the TMV 5' -terminal sequence (omega prime) . The mRNAs were translated in vitro in the systems derived from rabbit reticulocytes (MDL) , wheat-germ (WG) or E . coli (EC) .
The plasmids pJII6 and pJII7 (Figure 16) were constructed using components of plasmids pSP64CT and pSP64LT (Sleat e_t ai. Virology, 1_55. 299 (1986)) and pJIIIOl. Both pJIIδ and pJII7 are derivatives of the transcri tion plasmid pSP64 (Melton, 1984) , which contains a promoter for the bacteriophage SP6 RNA polymerase adjacent to the polylinker sequence derived from M13 mpll. The preprochymosin and prelysozyme coding regions of pSP64CT and pSP64LT respectively were excised as HindiII fragments, blunt-ended with the Klenow fragment of DNA polymerase 1, and cloned into the Hindi site of pJIIIOl to generate pJII6 and pJII7 respectively (Figure 16). These constructs were used to direct the synthesis of messenger-sense preprochymosin and prelysozyme transcripts bearing a 5' -terminal omega prime sequence. Parental plasmids pSP64CT and pSP64LT were templates for synthesis of mRNAs lacking omega prime. The results are shown in Table 7 below.
Tab l e 7
Effect of omega prime on expression of two eukaryotic mRNAs in 80S- and 70S - ribosome-based translation systems.
Incorporation of L- [ S ] -methionine (cpm) into gel- purified polype tides .
Cell-free system CPM (Rel. Stimulation)
MDL WG E. coli
SP6 transcript
Prelysozyme 5040 (1.0) 3730 (1.0) 0 (1.0) omega prime prelysozyme 5290 (1.0) 10240 (2.8) 1030 ( )
Preprochymosin 2470 (1.0) 1110 (1.0) 0 (1.0) omega prime preprochymosin 7280 (3.0) 10010 (9.1) 2180 ( ) In an analogous manner to the methods described above, various chimaeric RNA constructs were prepared with the NPT II coding region, and either omega prime, two tandem omega prime regions, a long (77 base) "junk" leader (polylinker) sequence or "junk" together with a central omega prime. The constructions are shown in Figure 17 and the results in Table 8 below: Tab l e 8
EFFECT OF VARIOUS 5' -LEADER CONSTRUCTIONS ON IN VITRO TRANSLATION OF S?6 TRANSCRIPTS OF NEOMYCIN PHOS HOTRANSFERASE
Cell-free Translation System Wheat Germ Rabbit reticul- E . coli ocyte lysate (-cap) (+cap) (-cap) (+cap) (-cap) (+cap)
NPTII 1* 1 1 1 1 1 omega prime NPTII 8.1+ _ 5.9 1.3 0.8 15.2 4.8 [ omega-omega] prime NPTII
8.2 6.3 1.1 0.7 44.9 15.0*
"JUNK" -NPTII 0.9 0.4 0.1 0.1 3.5 2.3
"JUNK" -omega prime NPTII
1.8 1.1 0.3 0.3 9.8 8.2
-^Background (H2O or linearized DNA) corrected / All values — Fold-stimulation over NPTII RNA alone.
This shows that a random polylinker sequence will not substitute for omega prime in 80S ribosome systems and only poorly in a prokaryotic (70S) system. Also two tandem omega primes only benefits 70S expression (c.f. single copy of omega prime) .
To extend the data presented in Table 6 (above) on the effect of omega prime on expression of the β- glucuronidase mRNA (GUS mRNA) , a new series of constructs utilized the GUS gene with a modified sequence context around the initiation codon (AUG) . Plasmid pRAJ275 , containing the "good context" leader ex SP6 plasmid Sal I 1 I -j
5 GAA UAC AAG CUU GGG CUG CAG GUC GAC C AUG G
Hind III was the source for this version of GUS. Omega prime and various other leader constructs, were inserted at the Hind Ill/Sal I sites as before. Details of the pRAJ275 construct are as follows: pRAJ275 is a derivative of pRAJ255 (Jefferson. e_t. al . Proc. Natl. Acad. Sci. 8_3_, 8447 (1986)) in which the 5' sequences of GUS were removed by progressive BAL31 deletion and replaced with a synthetic oligonucleotide that has constructed a "consensus" translational initiator as defined by Kozak (Microbiol. Reviews, 4_2, 1 (1983)) . This plasmid has a unique Nco I site (CCATGG) positioned at the initiator ATG codon, with the surrounding context GTCGACCATGGTC . It has been shown both in vitro and in vivo that the context around the initiator can have a profound effect on the levels of translated product from a given amount of mRNA. This construction has been adjusted to maximise this effect. It was provided as a Sal I- Eco RI fragment in pUC19.
5' -capped or uncapped transcripts were electroporated Into tobacco protoplasts as before and the level of GUS expression measured in extracts.
Uncapped RNAs were also added to MDL or WG cell-free translation systems and the level of GUS protein synthesized measured by excising and counting radioactive gel bands as for Figures 2, 3 etc. (Table 1). The results are shown in Table 9.
Table 9 Translational Enhancement by omega prime on GUS mRNA In vivo translation In vitro translation
Electroporated tobacco protoplasts MDL WG
Kozak Gus activity Fold Cpm 35< Fold Cpm 35< Fold context n oles 4-methyl sti - methionine- stimu¬ ethionine- stimu u belliferyl ulation labelled GUS lation labelled GUS latio gl curonide in gel bands in gel bands cleaved min-1 «g protein in
Uncapped protoplast
RNAs extract
GUS 235 bad <0.01 (1) 7180 (1.0) 2400 (1.0 (40b poly¬ s linker leader)
Omega prime-235 bad 0.18 (>18) 19700 (2.7) 9720 (4.1
GUS 275 good <0.01 (1) 12920 (1.0) 3010 (1.0 (28b poly¬ linker leader)
Omega good 0.35 (>35) 29280 (2.3) 19720 (6.6 prime-275
Cont/d.
Table 9 cont/d,
Translational Enhancement by omega prime on GUS mRNA In vivo translation
Electroporated tobacco protoplasts
Kozak Gus activity Fold context n oles 4-methyl stim- umbelliferyl ulation glucuronide cleaved min_1^ g protein in 5'capped protoplast c ω leader extract m
CO GUS 235 bad 0.03 (1) d (40b poly¬ linker c leader)
■s-
IYI Omega m prime-235 bad 0.61 (20) x m GUS 275 good 0.04 (1) (28b poly¬ linker leader)
Omega good 3.2 (80) prime-275
Again in all cases, both jLn vitro (MDL, G) and in vivo (protoplasts) with 5'capped or uncapped GUS mRNAs, with good or bad Kozak context around the initiation codon, omega prime enhances mRNA expression significantly.
A further set of RNA constructs was prepared, in an analogous manner to the method described above, with the E . coli reporter gene β - glucuronidase (GUS) and additionally the inducible trytophan (Trp) promoter. The Trp promoter was purchased from Pharmacia Ltd. ,. and modified by conventional techniques of restriction endonuclease digestion, filling-in, sub-cloning etc, to create a 3 ' -Hind III site (Fig. 18) and a blunt 5' -end. This dsDNA fragment was then inserted into the various leader-reporter (GUS) gene plasmids between the SP6 promoter (silent in E^ coli in vivo) and the 5' -leader const .uct of interest.
The resulting plasmid DNA was used to transform competent E ^ coli cells by standard techniques and the Trp promoter induced in situ to produce chimaeric leader- reporter. mRNAs. Transcription start point corresponds to the G. in the Hind III site (AAGCTT) .
Expression of the transcripts in transformed E . coli cells was determined spectrophotometrically (Jefferson et al . Proc. Natl. Acad. Sci. 8_3_ 8447 (1986)) . Results (Table 10) indicate that expression of GUS was enhanced i vivo from either the "good" or "bad" Kozak context construct by the presence of omega prime and to some extent by the other leader sequences or derivatives of omega prime. Tab l e 10
Expression controlled by the Trp promoter in stably transformed E . coli cells
Approximate relative spectro- photometric rates of conversion of p-nitrophenyl glucuronide
235-GUS ("Bad" context) 1 omega prime 235 GUS 7x
275-GUS ("Good" context) 1 omega prime-275 -GUS ("Good" context) 8x
Δ1-275-GUS ' 5 - 8x
Δ2 275 GUS (75x : To be confirmed)
Δ3 275 GUS (75x : To be confirmed)
Δ4 275 GUS 5 - 8x
Δ5 275 GUS 5 - 8x
A -> C 275 GUS (75x : To be confirmed)
[C,A]n -> [U]n 275 GUS 5x
TYMV 275 GUS 3 - 4x
A1MV4 275 GUS 3 - 4x
BMV3 275 GUS 1 - 2x
RSV 275 GUS 1 - 2x
(The results above were normalized to the respective GUS construct with the polylinker leader alone. *
Conclusions :
Omega prime enhances the expression of GUS RNA in vivo in E . coli transformed with plasmid DNAs , using Trp promoter in sItu.
Further experiments were performed using supercoiled double stranded pUC19 DNA which is modified to contain the cauliflower mosaic virus (CaMV) 35S promoter, the nopaline synthase terminator (from Agrobacterium tumefaciens ) and in between them either CAT DNA (*,A) or omega prime CAT DNA (0,Δ) .
The constructs (Figure 20) were prepared from a binary vector system (Bevan, Nuc Acids Res. .12. 8711 (1984)) wherein the CaMV 35S promoter and the Nos terminator were excised using Hind III and Eco RI sites and inserted into plasmid pUC19 thus giving pUC35S Nos.
The constructs pUC35SCATNos and pUC35S omega prime CATNos were made by inserting either CAT or omega prime CAT respectively into the plasmids using the Bam HI. site.
Various levels of either plasmid DNA (in μg/ml) were electroporated into protoplasts as before, and the cells incubated at 25°C for 6hours (0,*) or 26hours (Δ,Λ) and lysed. CAT assays (as before) were carried out.
The results as seen in Figure 20 indicate that cells which received lOOμg - 150μg of supercoiled plasmid DNA showed enhanced CAT expression (2 fold) when omega prime is present in the construct (Δ,0) . These results show that gene expression in stable transgenic plants will also likely be enhanced by the inclusion of the omega prime sequence between the promoter (for transcription in vivo) and the translational open r reading frame.

Claims

C LA I MS
1. Use of the 5 - leader sequence of an RNA virus up to the first initiation codon of the viral RNA (or a derivative or portion thereof) , either as RNA or as com lementary DNA, as an enhancer of translation of mRNA when the * 5' - leader is contiguous with the mRNA.
2. Use according to claim 1, in which the RNA virus is a plant virus .
3. Use according to claim 2, in which the plant virus is tobacco mosaic virus .
4. Use according to claim 3, in which the 5'- leader sequence is omega prime as herein defined, or a derivative or portion thereof.
5. Use according to any of claims 1 to 4, in which the 5' - leader sequence includes a 5'- cap.
6. mRNA including the 5' - leader sequence as defined in any of claims 1 to 5 , and downstream sequence not derived from the virus providing the leader sequence.
7. A DNA sequence complementary to the 5' - leader sequence as defined in any of claims 1 to 4.
8. A DNA sequence comprising a promoter, a sequence complementary to the 5' - leader sequence as defined in any of claims 1 to 4, and ah open reading frame including an appropriate initiation codon.
9. A DNA sequence according to claim 9, Including sequence used to enhance transcription.
1-0. An expression vector including a DNA sequence according to claim 8 or 9.
11. A living organism having incorporated in its cells a DNA sequence according to claim 8 or 9, whereby expression of the protein coded by the open reading frame is enhanced.
PCT/GB1987/000390 1986-06-04 1987-06-04 TRANSLATION OF mRNA WO1987007644A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE3750422T DE3750422T2 (en) 1986-06-04 1987-06-04 TRANSLATION OF MRNA.
EP87903719A EP0270611B1 (en) 1986-06-04 1987-06-04 TRANSLATION OF mRNA
US08/046,358 US5489527A (en) 1986-06-04 1993-04-12 Translation of m-RNA
US08/474,010 US5891665A (en) 1986-06-04 1995-06-07 Untranslated leader sequences from RNA viruses as enhancers of translation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8613481 1986-06-04
GB868613481A GB8613481D0 (en) 1986-06-04 1986-06-04 Translation of mrna

Publications (1)

Publication Number Publication Date
WO1987007644A1 true WO1987007644A1 (en) 1987-12-17

Family

ID=10598884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1987/000390 WO1987007644A1 (en) 1986-06-04 1987-06-04 TRANSLATION OF mRNA

Country Status (8)

Country Link
US (2) US5489527A (en)
EP (1) EP0270611B1 (en)
JP (2) JP2814433B2 (en)
AT (1) ATE110412T1 (en)
AU (1) AU614062B2 (en)
DE (1) DE3750422T2 (en)
GB (2) GB8613481D0 (en)
WO (1) WO1987007644A1 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000611A1 (en) * 1988-07-15 1990-01-25 Biosource Genetics Corporation Synthesis of stereospecific enzyme by non-chromosomal transformation of a host
WO1990002189A1 (en) * 1988-08-19 1990-03-08 The Upjohn Company Expression cassette for plants
EP0418695A1 (en) * 1989-09-13 1991-03-27 Ciba-Geigy Ag Regulatory DNA sequence
US5304731A (en) * 1988-08-17 1994-04-19 Japan Tobacco Inc. Vector
WO2001027260A1 (en) * 1999-10-15 2001-04-19 Wakenyaku Co., Ltd. Template molecule having broad applicability and highly efficient function means of cell-free synthesis of proteins by using the same
WO2002018586A1 (en) * 2000-08-30 2002-03-07 Wakenyaku Co Ltd Design and construction of transcription template for synthesizing cell-free protein, and dilution batch-type method of synthesizing cell-free wheat germ protein by using the same
WO2002036787A2 (en) 2000-10-30 2002-05-10 Bayer Cropscience S.A. Herbicide-tolerant plants through bypassing metabolic pathway
WO2004053134A1 (en) 2002-12-12 2004-06-24 Bayer Cropscience S.A. Expression cassette encoding a 5-enolpyruvylshikimate-3-phosphate synthase (epsps) and herbicide-tolerant plants containing it
US7166465B2 (en) 2001-02-22 2007-01-23 Rhobio Constitutive promoter from Arabidopsis
WO2010079117A2 (en) 2009-01-07 2010-07-15 Bayer Cropscience Ag Transplastomic plants free of the selectable marker
WO2011064224A1 (en) 2009-11-24 2011-06-03 Katholieke Universiteit Leuven, K.U.Leuven R&D Banana promoters
WO2011076892A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076877A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076889A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076885A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076882A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011095528A1 (en) 2010-02-04 2011-08-11 Bayer Cropscience Ag A method for increasing photosynthetic carbon fixation using glycolate dehydrogenase multi-subunit fusion protein
WO2011095460A1 (en) 2010-02-02 2011-08-11 Bayer Cropscience Ag Soybean transformation using hppd inhibitors as selection agents
EP2453012A1 (en) 2010-11-10 2012-05-16 Bayer CropScience AG HPPD variants and methods of use
EP2468882A1 (en) 2010-12-27 2012-06-27 Bayer CropScience AG Aurora kinase polypeptides for identifying fungicidal compounds
WO2012101118A1 (en) 2011-01-24 2012-08-02 Bayer Cropscience N.V. Use of the rd29 promoter or fragments thereof for stress-inducible expression of transgenes in cotton
WO2012130685A1 (en) 2011-03-25 2012-10-04 Bayer Cropscience Ag Use of n-(tetrazol-4-yl)- or n-(triazol-3-yl)arylcarboxamides or their salts for controlling unwanted plants in areas of transgenic crop plants being tolerant to hppd inhibitor herbicides
WO2012130684A1 (en) 2011-03-25 2012-10-04 Bayer Cropscience Ag Use of n-(1,2,5-oxadiazol-3-yl)benzamides for controlling unwanted plants in areas of transgenic crop plants being tolerant to hppd inhibitor herbicides
WO2012136788A1 (en) 2011-04-07 2012-10-11 Bayer Cropscience Nv Seed - specific promoter in cotton
WO2013023992A1 (en) 2011-08-12 2013-02-21 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
WO2013026740A2 (en) 2011-08-22 2013-02-28 Bayer Cropscience Nv Methods and means to modify a plant genome
WO2013053729A1 (en) 2011-10-12 2013-04-18 Bayer Cropscience Ag Plants with decreased activity of a starch dephosphorylating enzyme
WO2013053730A1 (en) 2011-10-12 2013-04-18 Bayer Cropscience Ag Plants with decreased activity of a starch dephosphorylating enzyme
WO2014043435A1 (en) 2012-09-14 2014-03-20 Bayer Cropscience Lp Hppd variants and methods of use
WO2014118123A1 (en) 2013-01-29 2014-08-07 The University Court Of The University Of Glasgow Methods and means for increasing stress tolerance and biomass in plants
WO2015000914A1 (en) 2013-07-01 2015-01-08 Bayer Cropscience Nv Methods and means for modulating flowering time in monocot plants
WO2015138394A2 (en) 2014-03-11 2015-09-17 Bayer Cropscience Lp Hppd variants and methods of use
WO2016014720A2 (en) 2014-07-22 2016-01-28 Nmc, Inc. Improved carbon fixation systems in plants and algae
WO2016050512A1 (en) 2014-10-03 2016-04-07 Bayer Cropscience Nv Methods and means for increasing stress tolerance and biomass in plants
WO2017042259A1 (en) 2015-09-11 2017-03-16 Bayer Cropscience Aktiengesellschaft Hppd variants and methods of use
WO2017184727A1 (en) 2016-04-21 2017-10-26 Bayer Cropscience Lp Tal-effector mediated herbicide tolerance
WO2018054911A1 (en) 2016-09-23 2018-03-29 Bayer Cropscience Nv Targeted genome optimization in plants
WO2018098214A1 (en) 2016-11-23 2018-05-31 Bayer Cropscience Lp Axmi669 and axmi991 toxin genes and methods for their use
WO2018119336A1 (en) 2016-12-22 2018-06-28 Athenix Corp. Use of cry14 for the control of nematode pests
WO2018136611A1 (en) 2017-01-18 2018-07-26 Bayer Cropscience Lp Use of bp005 for the control of plant pathogens
WO2018136604A1 (en) 2017-01-18 2018-07-26 Bayer Cropscience Lp Bp005 toxin gene and methods for its use
WO2018165091A1 (en) 2017-03-07 2018-09-13 Bayer Cropscience Lp Hppd variants and methods of use
US10093907B2 (en) 2013-09-24 2018-10-09 Basf Se Hetero-transglycosylase and uses thereof
US10273496B2 (en) 2014-12-17 2019-04-30 Basf Se Plants with improved photosynthetic carbon fixation capacity
WO2019083808A1 (en) 2017-10-24 2019-05-02 Basf Se Improvement of herbicide tolerance to hppd inhibitors by down-regulation of putative 4-hydroxyphenylpyruvate reductases in soybean
WO2019083810A1 (en) 2017-10-24 2019-05-02 Basf Se Improvement of herbicide tolerance to 4-hydroxyphenylpyruvate dioxygenase (hppd) inhibitors by down-regulation of hppd expression in soybean
WO2019233349A1 (en) 2018-06-04 2019-12-12 青岛清原化合物有限公司 Mutant p-hydroxyphenylpyruvate dioxygenase, and coding nucleic acid and use thereof

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135855A (en) * 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US5994526A (en) 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
US6303848B1 (en) 1998-01-16 2001-10-16 Large Scale Biology Corporation Method for conferring herbicide, pest, or disease resistance in plant hosts
US20030027173A1 (en) * 1998-01-16 2003-02-06 Della-Cioppa Guy Method of determining the function of nucleotide sequences and the proteins they encode by transfecting the same into a host
US6426185B1 (en) 1998-01-16 2002-07-30 Large Scale Biology Corporation Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation
US20020164585A1 (en) * 1998-01-16 2002-11-07 Sean Chapman Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
FI20000182A0 (en) * 2000-01-28 2000-01-28 Teemu Teeri Use of nucleotide sequences to increase protein synthesis and expression of proteins
JP4723713B2 (en) * 2000-09-25 2011-07-13 トヨタ自動車株式会社 Screening method for potential translational regulator of mRNA
EP1350846A4 (en) * 2000-12-07 2005-01-26 Univ Keio C-terminal modified protein and process for producing the same, modifying agent and translation template to be used in produfing c-terminal modified protein, and method of detecting protein interaction with the use of c-termial modified protein
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
WO2003106631A2 (en) * 2002-06-12 2003-12-24 Ambion, Inc. Methods and compositions relating to labeled rna molecules that reduce gene expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
BRPI0618236A2 (en) 2005-11-04 2011-08-23 Dow Agrosciences Llc preparation of major vaccine cell lines using recombinant plant suspension cultures
ITUD20060280A1 (en) * 2006-12-29 2008-06-30 Univ Degli Studi Udine ARTIFICIAL SEQUENCE OF DNA EVENT FUNCTION OF LEADER IN 5 '(5'-UTR) OPTIMIZED FOR THE OVEREXPRESSION OF HETEROLOGICAL PLANT PROTEINS
JP5048524B2 (en) 2007-03-08 2012-10-17 住友化学株式会社 Method for inducing and expressing foreign genes with chemical substances in plants
EP2352833B1 (en) * 2008-10-01 2013-03-06 TET Systems GmbH & Co. KG Tetracycline inducible transcription control sequence
US9222107B2 (en) 2011-05-25 2015-12-29 National University Corporation Okayama University REIC-expressing adenovirus vector
US11459579B2 (en) 2013-07-09 2022-10-04 Board Of Trustees Of Michigan State University Transgenic plants produced with a K-domain, and methods and expression cassettes related thereto
BR112015032956B1 (en) 2013-07-09 2022-09-13 Board Of Trustees Of Michigan State University METHOD TO PRODUCE A TRANSGENIC PLANT AND EXPRESSION CASSETTE
BR112019015797A2 (en) 2017-02-01 2020-03-17 Modernatx, Inc. IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS THAT CODE ACTIVATING ONCOGEN MUTATION PEPTIDES
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
US20200268666A1 (en) 2017-06-14 2020-08-27 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
MA50802A (en) 2017-11-22 2020-09-30 Modernatx Inc POLYNUCLEOTIDES CODING FOR ALPHA AND BETA SUB-UNITS OF PROPIONYL-COA CARBOXYLASE FOR THE TREATMENT OF PROPIONIC ACIDEMIA
EP3714048A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (en) 2018-09-02 2021-07-14 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR VERY LONG CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
MA53609A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED GLUCOSE-6-PHOSPHATASE FOR THE TREATMENT OF GLYCOGENOSIS
MA53608A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR THE E1-ALPHA, E1-BETA AND E2 SUBUNITS OF THE BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FOR THE TREATMENT OF LEUCINOSIS
JP2022500444A (en) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. A polynucleotide encoding polypeptide A1, a family of uridine diphosphate glycosyltransferases for the treatment of Crigler-Najer syndrome
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
EP3986480A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Messenger rna comprising functional rna elements and uses thereof
EP4045076A1 (en) 2019-10-15 2022-08-24 ModernaTX, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
CA3157859A1 (en) 2019-10-15 2021-04-22 Modernatx, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
AU2021205337A1 (en) 2020-01-10 2022-07-21 Modernatx, Inc. Methods of making tolerogenic dendritic cells
JP2023512072A (en) 2020-01-30 2023-03-23 モデルナティエックス インコーポレイテッド mRNA encoding metabolic reprogramming polypeptides and uses thereof
EP4149435A1 (en) 2020-05-14 2023-03-22 Modernatx, Inc. Lnp compositions comprising an mrna therapeutic and an effector molecule
WO2021247507A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
AU2021297248A1 (en) 2020-06-23 2023-02-02 Modernatx, Inc. LNP compositions comprising mRNA therapeutics with extended half-life
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US11566262B2 (en) 2021-03-24 2023-01-31 Dna Twopointo Inc. Tetracycline-inducible expression systems
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0067553A2 (en) * 1981-05-27 1982-12-22 National Research Council Of Canada An RNA plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
EP0194809B1 (en) * 1985-03-07 1991-03-13 Lubrizol Genetics Inc. Rna transformation vector

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485850T2 (en) * 1983-11-08 1993-01-21 Teijin Ltd GENE FRAGMENTS DERIVED FROM THE HUMAN IMMUNOGLOBULIN GENE.
DE3431140A1 (en) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg ENHANCER FOR EUKARYOTIC EXPRESSION SYSTEMS
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
JPS629984A (en) * 1985-07-08 1987-01-17 Ookura Eng Kk Apparatus for automatically selecting character
US4820639A (en) * 1985-12-04 1989-04-11 Massachusetts Institute Of Technology Process for enhancing translational efficiency of eukaryotic mRNA
CA1318619C (en) * 1986-04-09 1993-06-01 Brian William Grinnell Method of using eukaryotic expression vectors comprising the bk virus enhancer
US4962028A (en) * 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0067553A2 (en) * 1981-05-27 1982-12-22 National Research Council Of Canada An RNA plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
EP0194809B1 (en) * 1985-03-07 1991-03-13 Lubrizol Genetics Inc. Rna transformation vector

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Biochemistry, Vol. 22, 1983. American Chemical Society; L. GEHRKE et al. "5'-Conformation of Capped Alfalfa Mosaic Virus Ribonucleic Acid 4 May Reflect its Independence of the Cap Structure or of Cap-Binding Protein for Efficient Translation", pages 5157-5164, see the whole document *
Biological Abstracts, Biosciences Information Service, Vol. 82, No. 5, 1986 (Philiadelphia, PA, US L. GEHRKE: "Preparation of Messenger RNA Transcripts for Secondary Structure Analysis using SP6 Polymerase, Guanylytransferase and Preparative Gel Electrophoresis" see Abstract No. 40900, & Gene Anal. Tech, 3(3): 45-52, 1986 *
CHEMICAL ABSTRACTS, Vol. 103, 1985 (Columbus, Ohio, US) L. SUE LOESCH-FRIES et al.: "Expression of Alfalfa Mosaic Virus RNA 4 cDNA Transcripts in Vitro and in Vivo", see Abstract No. 190686, & Virology 1985, 146(2), 177-87 (Eng) *
CHEMICAL ABSTRACTS, Vol. 88, 1978 (Columbus, Ohio, US) K. RICHARDS et al.: "Nucleotide Sequence at the 5' Extremity of Tobacco Mosaic Virus RNA. 1. the Noncoding Region (Nucleotides 1-68)", see page 212, Abstract No. 165637t, & Eur. J. Biochem. 1978, 84(2), 513-19 (Eng). *
CHEMICAL ABSTRACTS, Vol. 89, 1978 (Columbus, Ohio, US) W. ZAGORSKI: "Translational Regulation of Expression of the Brome-Mosaic-Virus RNA Genome in Vitro", see page 213, Abstract No. 72850n, & Eur. J. Biochem. 1978, 86(2), 465-72 (Eng) *
Nature, Vol. 313, 28 February 1985 J.T. ODELL et al.: "Identification of DNA Sequences Required for Activity of the Cauliflower Mosaic Virus 35S Promoter", pages 810-812 *
Nature, Vol. 316, 15 August 1985 T. HUNT: "False Starts in Translational Control of Gene Expression" pages 580-581 see the whole document *
Nucleic Acids Research, Vol. 15, No. 8, 24 April 1987 D.R. GALLIE et al.: "The 5'-Leader Sequence of Tobacco Mosaic Virus RNA Enhances the Expression of Foreign Gene Transcripts in Vitro and in Vivo", pages 3257-3273, see the whole document *
Proc. Natl. Acad. Sci. (USA), Vol. 79, October 1982, Biochemistry P. GOELET et al.: "Nucleotide Sequence of Tobacco Mosaic Virus RNA", pages 5818-5822, see the whole document *
Proc. Natl. Acad. Sci., Vol. 83, March 1986, Genetics (US) W.O. DAWSON et al.: "cDNA Cloning of the Complete Genome of Tobacco Mosaic Virus and Production of Infectious Transcripts", pages 1832-1836, see the whole document *
Science, Vol. 231, 14 March 1986 R. FRENCH et al.: "Bacterial Gene Inserted in an Engineered RNA Virus: Efficient Expression in Monocotyledonous Plant Cells", pages 1294-1297, see the whole document *
The EMBO Journal, Vol. 4, No. 8, 1985; M.W. BEVAN et al.: "Expression of Tobacco Mosaic Virus Coat Protein by a Cauliflower Mosaic Virus Promoter in Plants Transformed by Agrobacterium", pages 1921-1926 *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000611A1 (en) * 1988-07-15 1990-01-25 Biosource Genetics Corporation Synthesis of stereospecific enzyme by non-chromosomal transformation of a host
US5304731A (en) * 1988-08-17 1994-04-19 Japan Tobacco Inc. Vector
WO1990002189A1 (en) * 1988-08-19 1990-03-08 The Upjohn Company Expression cassette for plants
US5998699A (en) * 1988-08-19 1999-12-07 Seminis Vegetable Seeds, Inc. Potyvirus coat protein genes and plants transformed therewith
EP0418695A1 (en) * 1989-09-13 1991-03-27 Ciba-Geigy Ag Regulatory DNA sequence
WO2001027260A1 (en) * 1999-10-15 2001-04-19 Wakenyaku Co., Ltd. Template molecule having broad applicability and highly efficient function means of cell-free synthesis of proteins by using the same
WO2002018586A1 (en) * 2000-08-30 2002-03-07 Wakenyaku Co Ltd Design and construction of transcription template for synthesizing cell-free protein, and dilution batch-type method of synthesizing cell-free wheat germ protein by using the same
WO2002036787A2 (en) 2000-10-30 2002-05-10 Bayer Cropscience S.A. Herbicide-tolerant plants through bypassing metabolic pathway
EP2141240A2 (en) 2000-10-30 2010-01-06 Bayer CropScience SA Plants that can tolerate herbicides by bypassing the metabolic route
US7166465B2 (en) 2001-02-22 2007-01-23 Rhobio Constitutive promoter from Arabidopsis
WO2004053134A1 (en) 2002-12-12 2004-06-24 Bayer Cropscience S.A. Expression cassette encoding a 5-enolpyruvylshikimate-3-phosphate synthase (epsps) and herbicide-tolerant plants containing it
WO2010079117A2 (en) 2009-01-07 2010-07-15 Bayer Cropscience Ag Transplastomic plants free of the selectable marker
WO2011064224A1 (en) 2009-11-24 2011-06-03 Katholieke Universiteit Leuven, K.U.Leuven R&D Banana promoters
WO2011076892A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076877A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076889A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076885A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011076882A1 (en) 2009-12-23 2011-06-30 Bayer Cropscience Ag Plants tolerant to hppd inhibitor herbicides
WO2011095460A1 (en) 2010-02-02 2011-08-11 Bayer Cropscience Ag Soybean transformation using hppd inhibitors as selection agents
WO2011095528A1 (en) 2010-02-04 2011-08-11 Bayer Cropscience Ag A method for increasing photosynthetic carbon fixation using glycolate dehydrogenase multi-subunit fusion protein
EP2669372A1 (en) 2010-11-10 2013-12-04 Bayer CropScience AG HPPD variants and methods of use
EP2453012A1 (en) 2010-11-10 2012-05-16 Bayer CropScience AG HPPD variants and methods of use
EP2669370A1 (en) 2010-11-10 2013-12-04 Bayer CropScience AG HPPD variants and methods of use
EP2669371A1 (en) 2010-11-10 2013-12-04 Bayer CropScience AG HPPD variants and methods of use
EP2669373A1 (en) 2010-11-10 2013-12-04 Bayer CropScience AG HPPD variants and methods of use
EP2669369A1 (en) 2010-11-10 2013-12-04 Bayer CropScience AG HPPD variants and methods of use
EP2468882A1 (en) 2010-12-27 2012-06-27 Bayer CropScience AG Aurora kinase polypeptides for identifying fungicidal compounds
WO2012101118A1 (en) 2011-01-24 2012-08-02 Bayer Cropscience N.V. Use of the rd29 promoter or fragments thereof for stress-inducible expression of transgenes in cotton
WO2012130685A1 (en) 2011-03-25 2012-10-04 Bayer Cropscience Ag Use of n-(tetrazol-4-yl)- or n-(triazol-3-yl)arylcarboxamides or their salts for controlling unwanted plants in areas of transgenic crop plants being tolerant to hppd inhibitor herbicides
WO2012130684A1 (en) 2011-03-25 2012-10-04 Bayer Cropscience Ag Use of n-(1,2,5-oxadiazol-3-yl)benzamides for controlling unwanted plants in areas of transgenic crop plants being tolerant to hppd inhibitor herbicides
WO2012136788A1 (en) 2011-04-07 2012-10-11 Bayer Cropscience Nv Seed - specific promoter in cotton
WO2013023992A1 (en) 2011-08-12 2013-02-21 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
US9670496B2 (en) 2011-08-22 2017-06-06 Bayer Cropscience N.V. Methods and means to modify a plant genome
US10538774B2 (en) 2011-08-22 2020-01-21 Basf Agricultural Solutions Seed, Us Llc Methods and means to modify a plant genome
WO2013026740A2 (en) 2011-08-22 2013-02-28 Bayer Cropscience Nv Methods and means to modify a plant genome
WO2013053729A1 (en) 2011-10-12 2013-04-18 Bayer Cropscience Ag Plants with decreased activity of a starch dephosphorylating enzyme
WO2013053730A1 (en) 2011-10-12 2013-04-18 Bayer Cropscience Ag Plants with decreased activity of a starch dephosphorylating enzyme
WO2014043435A1 (en) 2012-09-14 2014-03-20 Bayer Cropscience Lp Hppd variants and methods of use
EP3683307A2 (en) 2012-09-14 2020-07-22 BASF Agricultural Solutions Seed US LLC Hppd variants and methods of use
EP3173477A1 (en) 2012-09-14 2017-05-31 Bayer Cropscience LP Hppd variants and methods of use
WO2014118123A1 (en) 2013-01-29 2014-08-07 The University Court Of The University Of Glasgow Methods and means for increasing stress tolerance and biomass in plants
EP3431606A1 (en) 2013-07-01 2019-01-23 Bayer CropScience NV Methods and means for modulating flowering time in monocot plants
US10472645B2 (en) 2013-07-01 2019-11-12 Basf Se Methods and means for modulating flowering time in monocot plants
WO2015000914A1 (en) 2013-07-01 2015-01-08 Bayer Cropscience Nv Methods and means for modulating flowering time in monocot plants
US11447791B2 (en) 2013-07-01 2022-09-20 Basf Se Methods and means for modulating flowering time in monocot plants
US10093907B2 (en) 2013-09-24 2018-10-09 Basf Se Hetero-transglycosylase and uses thereof
US10647965B2 (en) 2013-09-24 2020-05-12 Basf Se Hetero-transglycosylase and uses thereof
WO2015138394A2 (en) 2014-03-11 2015-09-17 Bayer Cropscience Lp Hppd variants and methods of use
US10696977B2 (en) 2014-07-22 2020-06-30 Ncm, Inc. Carbon fixation systems in plants and algae
US11001853B2 (en) 2014-07-22 2021-05-11 Nmc, Inc. Carbon fixation systems in plants and algae
US11459578B2 (en) 2014-07-22 2022-10-04 Nmc, Inc. Carbon fixation systems in plants and algae
WO2016014720A2 (en) 2014-07-22 2016-01-28 Nmc, Inc. Improved carbon fixation systems in plants and algae
US10233458B2 (en) 2014-07-22 2019-03-19 Nmc, Inc. Carbon fixation systems in plants and algae
WO2016050512A1 (en) 2014-10-03 2016-04-07 Bayer Cropscience Nv Methods and means for increasing stress tolerance and biomass in plants
US10273496B2 (en) 2014-12-17 2019-04-30 Basf Se Plants with improved photosynthetic carbon fixation capacity
WO2017042259A1 (en) 2015-09-11 2017-03-16 Bayer Cropscience Aktiengesellschaft Hppd variants and methods of use
WO2017184727A1 (en) 2016-04-21 2017-10-26 Bayer Cropscience Lp Tal-effector mediated herbicide tolerance
WO2018054911A1 (en) 2016-09-23 2018-03-29 Bayer Cropscience Nv Targeted genome optimization in plants
WO2018098214A1 (en) 2016-11-23 2018-05-31 Bayer Cropscience Lp Axmi669 and axmi991 toxin genes and methods for their use
WO2018119336A1 (en) 2016-12-22 2018-06-28 Athenix Corp. Use of cry14 for the control of nematode pests
WO2018136604A1 (en) 2017-01-18 2018-07-26 Bayer Cropscience Lp Bp005 toxin gene and methods for its use
WO2018136611A1 (en) 2017-01-18 2018-07-26 Bayer Cropscience Lp Use of bp005 for the control of plant pathogens
WO2018165091A1 (en) 2017-03-07 2018-09-13 Bayer Cropscience Lp Hppd variants and methods of use
WO2019083810A1 (en) 2017-10-24 2019-05-02 Basf Se Improvement of herbicide tolerance to 4-hydroxyphenylpyruvate dioxygenase (hppd) inhibitors by down-regulation of hppd expression in soybean
WO2019083808A1 (en) 2017-10-24 2019-05-02 Basf Se Improvement of herbicide tolerance to hppd inhibitors by down-regulation of putative 4-hydroxyphenylpyruvate reductases in soybean
WO2019233349A1 (en) 2018-06-04 2019-12-12 青岛清原化合物有限公司 Mutant p-hydroxyphenylpyruvate dioxygenase, and coding nucleic acid and use thereof

Also Published As

Publication number Publication date
AU7489687A (en) 1988-01-11
JPH01500961A (en) 1989-04-06
GB2199328B (en) 1990-10-24
US5489527A (en) 1996-02-06
JP3658654B2 (en) 2005-06-08
JPH10146197A (en) 1998-06-02
ATE110412T1 (en) 1994-09-15
DE3750422D1 (en) 1994-09-29
DE3750422T2 (en) 1994-12-15
EP0270611B1 (en) 1994-08-24
US5891665A (en) 1999-04-06
GB2199328A (en) 1988-07-06
GB8801508D0 (en) 1988-03-16
JP2814433B2 (en) 1998-10-22
AU614062B2 (en) 1991-08-22
GB8613481D0 (en) 1986-07-09
EP0270611A1 (en) 1988-06-15

Similar Documents

Publication Publication Date Title
US5489527A (en) Translation of m-RNA
Gallie et al. The 5'-leader sequence of tobacco mosaic virus RNA enhances the expression of foreign gene transcripts in vitro and in vivo
AU594665B2 (en) Phenotypic modifications of host cells via RNA transformation vector
Gallie et al. RNA pseudoknot domain of tobacco mosaic virus can functionally substitute for a poly (A) tail in plant and animal cells.
Gallie et al. A comparison of eukaryotic viral 5′-leader sequences as enhancers of mRNA expression in vivo
US5173410A (en) Transfer vector
US5034322A (en) Chimeric genes suitable for expression in plant cells
Mott et al. Maturation of Escherichia coli tryptophan operon mRNA: evidence for 3′ exonucleolytic processing after rho‐dependent termination.
US5162601A (en) Plant potyvirus expression vector with a gene for protease
US4885248A (en) Transfer vector
US6174724B1 (en) Chimeric genes suitable for expression in plant cells
Taylor et al. Optimizing the expression of chimeric genes in plant cells
US5773705A (en) Ubiquitin fusion protein system for protein production in plants
Nilsson et al. In vivo and in vitro identity of site specific cleavages in the 5′ non‐coding region of ompA and bla mRNA in Escherichia coli.
Grummt et al. Efficient transcription of a protein-coding gene from the RNA polymerase I promoter in transfected cells.
Gallie et al. Functional analysis of the tobacco mosaic virus tRNA-like structure in cytoplasmic gene regulation
WO1987003619A1 (en) PROCESS FOR ENHANCING TRANSLATIONAL EFFICIENCY OF EUKARYOTIC mRNA
EP0988387B9 (en) Recombinant construct for enhancement of gene expression in plants
JP2574142B2 (en) Recombinant ricin toxin fragment
US5910628A (en) Cap-independent translation sequences derived from barley yellow dwarf virus
US5612193A (en) Translation of mRNA
Andersen et al. Attenuation in the rph‐pyrE operon of Escherichia coli and processing of the dicistronic mRNA
IE59562B1 (en) Method for preparing proteins using transformed lactic acid bacteria
JP2000350581A (en) Control over function of gene
US4585739A (en) Plasmid for foreign gene expression in B. subtilis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 8801508.6

Country of ref document: GB

AK Designated states

Kind code of ref document: A1

Designated state(s): AU GB JP SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987903719

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987903719

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1987903719

Country of ref document: EP